|
Page Content Tuas Biomedical Park (TBP) is a world-class manufacturing hub, hosting process development and manufacturing operations of major pharmaceutical, biotechnology and medical technology companies. Located at the western tip of Singapore, the TBP is only 60 minutes from Changi International Airport, 5 minutes from the Tuas Checkpoint to Malaysia and 20 minutes away from Jurong Port. The 312 ha TBP is strategically located to provide companies with access to skilled talent, research expertise, and air and sea logistics.
Leading global biomedical companies have invested in about 20 commercial-scale facilities in Singapore, which houses process development operations and manufacture of active pharmaceutical ingredients (APIs) and novel medicines. Both Pfizer and MSD GmbH have partnered Tuas Power, a leading Singapore based energy and utilities solutions provider, to develop state-of-the-art trigeneration facilities.
Key Customers
TBP is home to a host of global biomedical players, including GlaxoSmithKline, Lonza, MSD GmbH, Novartis, Pfizer and Roche.
Roche has invested to set up two biologics facilities within the estate. The firm is a leading developer of some of the latest cancer drugs, and the facilities will house Singapore's first microbial-based bulk biopharmaceutical manufacturing operation.
Swiss life sciences company Lonza is also building two manufacturing plants for mammalian cell-derived products, investing a total of about US$600 million.
Novartis spent US$448 million setting up a state-of-the-art cell-culture facility. The facility will support the clinical and commercial production of protein-based drugs for various medical conditions such as arthritis, cancer, asthma and spinal cord injury. Novartis's Singapore facility is its largest investment in 140 countries.
|